Guiyang Xintian Pharmaceutical Co., Ltd. was founded in August 1995 and was listed on the Shenzhen Stock Exchange Small and Medium Enterprises Board on May 19, 2017. The stock abbreviation is: Xintian Pharmaceutical, stock code: 002873. The company belongs to the traditional Chinese medicine production industry in the pharmaceutical manufacturing industry, and has eight dosage form production lines, including hard capsules, mixtures, granules, gels, tablets, syrups, wines, and dews, as well as Chinese herbal decoction A line that has passed GMP certification. Two lines of line B. The company is mainly engaged in the research, development, production and sales of traditional Chinese patent medicine products for urinary diseases, gynecological and other complex diseases, and provides patients with safe and effective products.

The company currently produces 11 products, and its leading products are Ningbitai Capsules, Kuntai Capsules, Sophora Gel, and Xia Kucao Oral Liquid.

The company arranges R&D activities in accordance with the requirements of "production, reserve, and development". After more than ten years of development, the company's R&D work has accumulated to a certain extent, which can fully meet the company's new product launch needs. The company currently produces 11 products, of which 4 are currently mainly in product varieties. There are 7 varieties that plan to switch from small batch production to mass production in the future; there are 2 varieties that have been approved for registration in the future. The abundant variety reserves provide guarantees for the company's rapid development in the future.

The company has always attached importance to R&D work, and regards R&D capabilities as one of the main factors for the company to achieve sustainable development and an important part of the company's core competitiveness. The company currently has 40 invention patents, 1 utility model patent and 5 appearance patents. 11 national new drug certificates and 54 drug approval documents have been obtained.

In recent years, on the basis of accurately grasping the direction of national medical reform and the development trend of traditional Chinese patent medicine sales, the company has adhered to "sales service, promotion specialization, and product quality", and vigorously strengthened its own marketing management system construction to adapt to the entry of the company's leading products. New situation in the National Medical Insurance Directory and the National Basic Drug Directory. Secondly, the manager responsibility system is implemented in various regional markets, and a professional division of labor is implemented for market sales personnel to further strengthen the academic promotion and the depth of service marketing.

Through professional academic promotion, the company has increased the trust of clinical medical personnel in the company and the company's drugs, effectively maintaining the relationship between the company, pharmaceutical commercial companies and hospitals. In addition, the company has accumulated over the years of construction and formed professional and stable The marketing team, the company has outstanding marketing advantages.